• Home
  • The Science
  • Nu.Q® Pipeline
    • Nu.Q®
    • Nu.Q® NETs
    • Nu.Q® Vet
    • Nu.Q® Capture
    • Nu.Q® Discover
  • About Us
    • Our Values
    • Our Expert Team
    • Contact Us
  • Investors
  • Resources
    • News Room
    • Scientific
    • Investors
    • Veterinary Resources
  • Join Mailing List
Volition
  • Home
  • The Science
  • Nu.Q® Pipeline
    • Nu.Q®
    • Nu.Q® NETs
    • Nu.Q® Vet
    • Nu.Q® Capture
    • Nu.Q® Discover
Volition
  • About Us
    • Our Values
    • Our Expert Team
    • Contact Us
  • Investors
  • Resources
    • News Room
      • Press Releases
      • Video Gallery
      • Media Toolkit
      • Downloads
    • Scientific
      • Clinical Papers & Posters
      • Presentations
      • Video Gallery
    • Investors
      • Presentations
      • Video Gallery
    • Veterinary Resources
  • Join Mailing List

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Shareholders Letters
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Executive Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • Shareholders Letters
  • IR Calendar
  • Presentations
  • Email Alerts
May 11, 2022 4:10pm EDT

VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update

May 06, 2022 8:00am EDT

VolitionRx Limited Schedules First Quarter 2022 Earnings Conference Call and Business Update

May 05, 2022 8:03am EDT

VolitionRx Limited to Host Capital Markets Day on Friday May 13

Apr 25, 2022 8:00am EDT

Volition Launches its Nu.Q® Vet Cancer Test in Asia Through its Appointed Distributor SAGE Healthcare

Apr 06, 2022 8:00am EDT

Volition appoints Sharon Ballesteros as U.S. Head of Quality and Development Process

Mar 30, 2022 4:10pm EDT

VolitionRx Limited Announces Full Fiscal Year 2021 Financial Results and Business Update

Mar 29, 2022 8:00am EDT

Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Cancer Screening Test at the Point of Care

Mar 28, 2022 4:25pm EDT

VolitionRx Limited Schedules Full Fiscal Year 2021 Earnings Conference Call and Business Update

Jan 20, 2022 8:30am EST

Volition presents study data at ASCO GI 2022 on circulating nucleosomes for the detection of colorectal cancer and high-risk advanced adenomas

Dec 16, 2021 8:00am EST

Volition Executes its First Supply and Licensing Contract for its Nu.Q® Vet Cancer Screening Test in Asia

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 31
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Contact Us
  • Downloads
  • Privacy Policy
  • Disclaimer
  • Manage Cookie Preferences
Sign up to  email alerts
linkedin facebook twitter
artboard

The European Regional Development Fund and Wallonia are investing in your future

http://europe.wallonie.be
artboard
artboard

The European Regional Development Fund and Wallonia are investing in your future

http://europe.wallonie.be
artboard

MENAC - Epigenetic Modifications of Nucleosomes Associated with Cancer

Thanks to a grant of 1.990.798€ from the European Regional Development Fund and Walloon Government, we’re taking part in the MENAC project which aims to develop innovative non-invasive tests for the early detection of different types of cancer. We’re working in partnership with Synabs to create monoclonal antibodies and develop new diagnostic and theragnostic immunoassays.